144 related articles for article (PubMed ID: 14710228)
1. G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis.
Jézéquel P; Campion L; Joalland MP; Millour M; Dravet F; Classe JM; Delecroix V; Deporte R; Fumoleau P; Ricolleau G
Br J Cancer; 2004 Jan; 90(1):189-93. PubMed ID: 14710228
[TBL] [Abstract][Full Text] [Related]
2. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.
Thussbas C; Nahrig J; Streit S; Bange J; Kriner M; Kates R; Ulm K; Kiechle M; Hoefler H; Ullrich A; Harbeck N
J Clin Oncol; 2006 Aug; 24(23):3747-55. PubMed ID: 16822847
[TBL] [Abstract][Full Text] [Related]
3. FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.
Spinola M; Leoni VP; Tanuma J; Pettinicchio A; Frattini M; Signoroni S; Agresti R; Giovanazzi R; Pilotti S; Bertario L; Ravagnani F; Dragani TA
Oncol Rep; 2005 Aug; 14(2):415-9. PubMed ID: 16012724
[TBL] [Abstract][Full Text] [Related]
4. Re-evaluating the FGFR4 (G388R) germline mutation in different cancers in Pakistani population.
Mansoor Q; Fayyaz S; Farooqi AA; Bhatti S; Ismail M
J Exp Ther Oncol; 2013; 10(3):215-7. PubMed ID: 24416997
[TBL] [Abstract][Full Text] [Related]
5. Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.
Bange J; Prechtl D; Cheburkin Y; Specht K; Harbeck N; Schmitt M; Knyazeva T; Müller S; Gärtner S; Sures I; Wang H; Imyanitov E; Häring HU; Knayzev P; Iacobelli S; Höfler H; Ullrich A
Cancer Res; 2002 Feb; 62(3):840-7. PubMed ID: 11830541
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast growth factor receptor 4 protein expression and clinicopathological features in gastric cancer.
Chen H; Shen DP; Zhang ZZ; Liu JH; Shen YY; Ni XZ
World J Gastroenterol; 2015 Feb; 21(6):1838-44. PubMed ID: 25684949
[TBL] [Abstract][Full Text] [Related]
7. Influence of the fibroblast growth factor receptor 4 expression and the G388R functional polymorphism on Cushing's disease outcome.
Brito LP; Lerário AM; Bronstein MD; Soares IC; Mendonca BB; Fragoso MC
J Clin Endocrinol Metab; 2010 Oct; 95(10):E271-9. PubMed ID: 20660043
[TBL] [Abstract][Full Text] [Related]
8. Loss of heterozygosity and DNA methylation affect germline fibroblast growth factor receptor 4 polymorphism to direct allelic selection in breast cancer.
Zhu X; Zheng L; Asa SL; Ezzat S
Am J Pathol; 2010 Dec; 177(6):2860-9. PubMed ID: 21037081
[TBL] [Abstract][Full Text] [Related]
9. FGFR4: A promising therapeutic target for breast cancer and other solid tumors.
Levine KM; Ding K; Chen L; Oesterreich S
Pharmacol Ther; 2020 Oct; 214():107590. PubMed ID: 32492514
[TBL] [Abstract][Full Text] [Related]
10. Prognostic implications of fibroblast growth factor receptor 4 polymorphisms in primary breast cancer.
Wei W; You Z; Sun S; Wang Y; Zhang X; Pang D; Jiang Y
Mol Carcinog; 2018 Aug; 57(8):988-996. PubMed ID: 29603419
[TBL] [Abstract][Full Text] [Related]
11. The fibroblast growth factor receptor-4 Arg388 allele is associated with gastric cancer progression.
Ye Y; Shi Y; Zhou Y; Du C; Wang C; Zhan H; Zheng B; Cao X; Sun MH; Fu H
Ann Surg Oncol; 2010 Dec; 17(12):3354-61. PubMed ID: 20844967
[TBL] [Abstract][Full Text] [Related]
12. Polymorphism of FGFR4 Gly388Arg does not confer an increased risk to breast cancer development.
Naidu R; Har YC; Taib NA
Oncol Res; 2009; 18(2-3):65-71. PubMed ID: 20066896
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer.
Overgaard J; Yilmaz M; Guldberg P; Hansen LL; Alsner J
Acta Oncol; 2000; 39(3):327-33. PubMed ID: 10987229
[TBL] [Abstract][Full Text] [Related]
14. FGFR4 Arg388 allele correlates with tumour thickness and FGFR4 protein expression with survival of melanoma patients.
Streit S; Mestel DS; Schmidt M; Ullrich A; Berking C
Br J Cancer; 2006 Jun; 94(12):1879-86. PubMed ID: 16721364
[TBL] [Abstract][Full Text] [Related]
15. Effects of FGFR4 G388R, V10I polymorphisms on the likelihood of cancer.
Peng T; Sun Y; Lv Z; Zhang Z; Su Q; Wu H; Zhang W; Yuan W; Zuo L; Shi L; Zhang LF; Zhou X; Mi Y
Sci Rep; 2021 Jan; 11(1):1373. PubMed ID: 33446698
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphism in fibroblast growth factor receptor 4 at codon 388 is associated with prognosis in high-grade soft tissue sarcoma.
Morimoto Y; Ozaki T; Ouchida M; Umehara N; Ohata N; Yoshida A; Shimizu K; Inoue H
Cancer; 2003 Nov; 98(10):2245-50. PubMed ID: 14601095
[TBL] [Abstract][Full Text] [Related]
17. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
[TBL] [Abstract][Full Text] [Related]
18. Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma.
Streit S; Bange J; Fichtner A; Ihrler S; Issing W; Ullrich A
Int J Cancer; 2004 Aug; 111(2):213-7. PubMed ID: 15197773
[TBL] [Abstract][Full Text] [Related]
19. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Role of the FGFR4-388Arg Variant in Lung Squamous-Cell Carcinoma Patients With Lymph Node Involvement.
Quintanal-Villalonga Á; Carranza-Carranza A; Meléndez R; Ferrer I; Molina-Pinelo S; Paz-Ares L
Clin Lung Cancer; 2017 Nov; 18(6):667-674.e1. PubMed ID: 28583379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
